Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse

Xavier Thomas, MD PhD, Anita W Rijneveld, MD PhD, Nicola Fracchiolla, MD, Cyril Šálek, MD, Alexandros Spyridonidis, MD PhD, Sabina Chiaretti, MD PhD, Naufil Alam, PhD, Isabella Pezzani Grueter, PharmD, Abeera Mohammad, MSc, William Kormany, MD, Georg Kreuzbauer, MD, Alessandro Rambaldi, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134470

Published: 2020

Journal Articles

The Validation of the BCR/ABL1 -like Predictor across Laboratories Shows Reproducibility of Results

Sabina Chiaretti, MD PhD, Taherinasab Akram, Canichella Martina, Monica Messina, Alfonso Piciocchi, Cyril Šálek, MD PhD, Katerina Machova, Katerina Blagoevova, Jordi Ribera, PhD, Josep-Maria Ribera, MD PhD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Anna Guarini, PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5211.

https://doi.org/10.1182/blood-2019-122116

Published: 2019

Journal Articles

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Michela Ansuinelli, MD, Antonella Vitale, MD, Giovanna Pecoraro, MD, Saveria Capria, MD, Silvia Maria Trisolini, MD, Clara Minotti, MD, Claudio Cartoni, MD, Anna Maria Testi, MD, Maria Luisa Moleti, MD, Anna Paola Iori, MD, Walter Barberi, MD PhD, Irene Della Starza, PhD, Loredana Elia, Bs, Francesca Mancini, Maria Stefania De Propris, Anna Guarini, PhD, Sabina Chiaretti, MD PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5121.

https://doi.org/10.1182/blood-2019-128156

Published: 2019

Journal Articles

Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study

Nicolas Boissel, MD PhD, Renato Bassan, MD, Josep-Maria Ribera, MD PhD, Sabina Chiaretti, MD PhD, Robin Foà, MD, Cristina Papayannidis, Naufil Alam, MSc, Alessandra Brescianini, PharmD, Isabella Pezzani, PharmD, Georg Kreuzbauer, MD, Alessandro Rambaldi, MD PhD

Blood (2019) 134 (Supplement_1): 2624.

https://doi.org/10.1182/blood-2019-122931

Published: 2019

Journal Articles

Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study

Nicolas Boissel, MD PhD, Josep-Maria Ribera, MD PhD, Sabina Chiaretti, MD PhD, Alessandro Rambaldi, MD, Renato Bassan, MD, Cristina Papayannidis, Naufil Alam, MSc, Alessandra Brescianini, PharmD, Isabella Pezzani, PharmD, Georg Kreuzbauer, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 2627.

https://doi.org/10.1182/blood-2019-122917

Published: 2019

Journal Articles

Prognostic Impact of t(4;11)(q21;q23)/ KMT2A-AFF1 -Positivity in 926 BCR-ABL1 -Negative B-Lineage Acute Lymphoblastic Leukemia Patients Treated in Gimema Clinical Trials Since 1996

Alfonso Piciocchi, Monica Messina, Loredana Elia, Bs, Antonella Vitale, MD, Stefano Soddu, Anna Maria Testi, MD, Sabina Chiaretti, MD PhD, Marco Mancini, MD, Giorgina Specchia, MD, Antonio Spadano, MD, Mauro Krampera, Roberto Cairoli, MD, Francesco Di Raimondo, MD, Felicetto Ferrara, MD, Giuseppe Cimino, MD, Renato Bassan, MD, Paola Fazi, MD, Marco Vignetti, MD

Blood (2019) 134 (Supplement_1): 1469.

https://doi.org/10.1182/blood-2019-121977

Published: 2019

Journal Articles

Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial

Sabina Chiaretti, MD PhD, Renato Bassan, MD, Antonella Vitale, MD, Loredana Elia, Bs, Alfonso Piciocchi, Cristina Puzzolo, PhD, Martina Canichella, MD, Felicetto Ferrara, MD, Monia Lunghi, MD PhD, Francesco Fabbiano, MD, Massimiliano Bonifacio, MD, Nicola Fracchiolla, Prassede Salutari, MD, Alessandra Mancino, Bs, Marco Vignetti, MD, Anna Guarini, PhD, Alessandro Rambaldi, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 740.

https://doi.org/10.1182/blood-2019-128759

Published: 2019

Journal Articles

Comparative Analysis between RQ-PCR, Digital-Droplet-PCR and Next-Generation-Sequencing (NGS) of Immunoglobulin/T-Cell Receptor Gene Rearrangements to Monitor Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia Patients

Irene Della Starza, PhD, Lucia Anna De Novi, PhD, Alessandra Santoro, PhD, Salemi Domenico, PhD, Marzia Cavalli, PhD, Roberta Soscia, Francesca Paoloni, Lucia Menale, Valerio Apicella, Caterina Ilari, PhD, Antonella Vitale, Marco Vignetti, MD, Renato Bassan, MD, Sabina Chiaretti, MD PhD, Anna Guarini, PhD, Robin Foà, MD

Blood (2018) 132 (Supplement 1): 2828.

https://doi.org/10.1182/blood-2018-99-118219

Published: 2018

Journal Articles

Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL).

Blood (2012) 120 (21): 2497.

https://doi.org/10.1182/blood.V120.21.2497.2497

Published: 2012

Journal Articles

NOTCH1 , SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment

Sabina Chiaretti, MD, PhD, Marilisa Marinelli, PhD, Ilaria Del Giudice, MD, PhD, Silvia Bonina, PhD student, Sara Gabrielli, Miss, Alfonso Piciocchi, Monica Messina, PhD, Marco Vignetti, MD, Davide Rossi, MD, PhD, Valeria Di Maio, Miss, Francesca Romana Mauro, MD, Anna Guarini, PhD, Gianluca Gaidano, MD, PhD, Robin Foà, MD

Blood (2012) 120 (21): 1784.

https://doi.org/10.1182/blood.V120.21.1784.1784

Published: 2012

Journal Articles

The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories

Blood (2012) 120 (21): 1399.

https://doi.org/10.1182/blood.V120.21.1399.1399

Published: 2012

Journal Articles

Gene Expression Profile Reveals a Unique Pattern of Protein Kinases in Chronic Lymphocytic Leukemia (CLL): Potential Role of the Second Generation Protein Kinase Inhibitors.

Simona Tavolaro, BS, Sabina Chiaretti, MD, PhD, Monica Messina, BS, Nadia Peragine, BS, Roberta Maggio, BS, Ilaria Del Giudice, MD, PhD, Emanuela M. Ghia, PhD, Francesca R. Mauro, MD, Anna Guarini, PhD, Robert Foa, MD

Blood (2007) 110 (11): 3117.

https://doi.org/10.1182/blood.V110.11.3117.3117

Published: 2007

Journal Articles

Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.

Michele Milella, MD, Sabina Chiaretti, MD, PhD, Maria R. Ricciardi, PhD, Simona Tavolaro, BSc, Ludovica Ciuffreda, PhD, Barbara Benassi, PhD, Alfonso Bellacosa, MD, PhD, Gianfranco Peluso, PhD, Paola Bergamo, MS, James A. McCubrey, PhD, Francesco Cognetti, MD, Gabriella Zupi, PhD, Robert Foà, MD, Agostino Tafuri, MD

Blood (2007) 110 (11): 3470.

https://doi.org/10.1182/blood.V110.11.3470.3470

Published: 2007

Journal Articles

IgV H Germline and Mutated Chronic Lymphocytic Leukemia (CLL) Cases Exert a Diverse Responsiveness upon BCR Ligation.

Simona Tavolaro, BS, Roberta Maggio, BS, Nadia Peragine, BS, Monica Messina, BS, Franca Citarella, PhD, Simona Santangelo Miss, Marilisa Marinelli, BS, Maria R. Ricciardi, PhD, Maria S. De Propris, PhD, Ilaria Del Giudice, MD, PhD, Francesca R. Mauro, MD, Sabina Chiaretti, MD, PhD, Robert Foa, MD, Anna Guarini, PhD

Blood (2007) 110 (11): 1133.

https://doi.org/10.1182/blood.V110.11.1133.1133

Published: 2007

Journal Articles

Gene Expression Profile of Protein Kinases Reveals a Distinctive Signature of Chronic Lymphocytic Leukemia (CLL) and Points to a Role of Second Generation Protein Kinase Inhibitors.

Simona Tavolaro, BS, Sabina Chiaretti, MD, PhD, Monica Messina, BS, Francesca R. Mauro, MD, Ilaria Del Giudice, MD PhD, Roberta Maggio, BS, Emanuela M. Ghia, BS, Marilisa Marinelli, BS, Simona Santangelo Miss, Anna Guarini, PhD, Robert Foa, MD

Blood (2006) 108 (11): 2794.

https://doi.org/10.1182/blood.V108.11.2794.2794

Published: 2006

Journal Articles

Protein Kinase Gene Expression Profile in Adult Acute Lymphocytic Leukemia (ALL): Identification of Novel Therapeutic Targets.

Monica Messina, BS, Sabina Chiaretti, MD, PhD, Simona Tavolaro, BS, Irene Della Starza Miss, Antonella Vitale, MD, Cristina Ariola, BS, Alina Negulici Miss, Loredana Elia, PhD, Anna Guarini, PhD, Robert Foa, MD

Blood (2006) 108 (11): 1824.

https://doi.org/10.1182/blood.V108.11.1824.1824

Published: 2006

Journal Articles

The MicroRNA (miR) Profile in B-Cell Chronic Lymphocytic Leukemia (CLL) Reveals a Differential Expression of miR-21, miR-155 and miR-150 between Leukemic and Normal B Lymphocytes, and of miR-150, miR-29bc and miR-223 between IgV H Mutated and Unmutated Patients.

Sabina Chiaretti, MD, PhD, Valerio Fulci, PhD, Marina Goldoni, BS, Gianluca Azzalin, Mr, Simona Tavolaro, BS, Monica Messina, BS, Roberta Maggio, BS, Nadia Peragine, BS, Simona Santangelo Miss, Francesca R. Mauro, MD, Anna Guarini, PhD, Giuseppe Macino, PhD, Robert Foa, MD

Blood (2006) 108 (11): 298.

https://doi.org/10.1182/blood.V108.11.298.298

Published: 2006

Journal Articles

Angiogenic Activity in IgV H Mutated and Unmutated Chronic Lymphocytic Leukemia (CLL): Indications for the Therapeutic Use of VEGF-Signaling Inhibitors.

Roberta Maggio, BS, Nadia Peragine, BS, Monica Messina, BS, Sabina Chiaretti, MD PhD, Stefania M. De Propris, PhD, Simona Tavolaro, BS, Marilisa Marinelli, BS, Elisabetta Calabrese, BS, Ilaria Del Giudice, MD PhD, Francesca R. Mauro, MD, Anna Guarini, PhD, Robert Foa, MD

Blood (2006) 108 (11): 2819.

https://doi.org/10.1182/blood.V108.11.2819.2819

Published: 2006

Journal Articles

Effective Targeting of MEK/ERK Signalling at Nanomolar Concentrations by the Novel Small Molecule Inhibitor PD0325901 in Hematopoietic and Solid Tumors.

Maria R. Ricciardi, PhD, Maria C. Scerpa, PhD, Ludovica Ciuffreda, PhD, Sabina Chiaretti, MD, PhD, Simona Tavolaro, PhD, Jacopo Gervasoni, Fabiana De Cave, PhD, Chiara Gregorj, PhD, Maria T. Petrucci, MD, Francesco Cognetti, MD, Michael Andreeff, MD, PhD, Gabriella Zupi, MD, Robin Foà, MD, Agostino Tafuri, MD, Michele Milella, MD

Blood (2005) 106 (11): 3370.

https://doi.org/10.1182/blood.V106.11.3370.3370

Published: 2005

Journal Articles

Detection of the NUP214-ABL Rearrangement in T-ALL by High-Density Oligonucleotide Arrays: Evidence of the Value of This Approach in the Identification of Gene Amplifications.

Sabina Chiaretti, MD, PhD, Simona Tavolaro, BSc, Emanuela Ghia, BSc, Cristina Ariola, BSc, Caterina Matteucci, BSc, Roberta Maggio, BSc, Antonella Vitale, MD, Jerome Ritz, MD, Cristina Mecucci, MD, Anna Guarini, PhD, Robert Foà, MD

Blood (2005) 106 (11): 1211.

https://doi.org/10.1182/blood.V106.11.1211.1211

Published: 2005

NARROW

Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse

The Validation of the BCR/ABL1 -like Predictor across Laboratories Shows Reproducibility of Results

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study

Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study

Prognostic Impact of t(4;11)(q21;q23)/ KMT2A-AFF1 -Positivity in 926 BCR-ABL1 -Negative B-Lineage Acute Lymphoblastic Leukemia Patients Treated in Gimema Clinical Trials Since 1996

Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial

Comparative Analysis between RQ-PCR, Digital-Droplet-PCR and Next-Generation-Sequencing (NGS) of Immunoglobulin/T-Cell Receptor Gene Rearrangements to Monitor Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia Patients

Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL).

NOTCH1 , SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment

The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories

Gene Expression Profile Reveals a Unique Pattern of Protein Kinases in Chronic Lymphocytic Leukemia (CLL): Potential Role of the Second Generation Protein Kinase Inhibitors.

Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.

IgV H Germline and Mutated Chronic Lymphocytic Leukemia (CLL) Cases Exert a Diverse Responsiveness upon BCR Ligation.

Gene Expression Profile of Protein Kinases Reveals a Distinctive Signature of Chronic Lymphocytic Leukemia (CLL) and Points to a Role of Second Generation Protein Kinase Inhibitors.

Protein Kinase Gene Expression Profile in Adult Acute Lymphocytic Leukemia (ALL): Identification of Novel Therapeutic Targets.

The MicroRNA (miR) Profile in B-Cell Chronic Lymphocytic Leukemia (CLL) Reveals a Differential Expression of miR-21, miR-155 and miR-150 between Leukemic and Normal B Lymphocytes, and of miR-150, miR-29bc and miR-223 between IgV H Mutated and Unmutated Patients.

Angiogenic Activity in IgV H Mutated and Unmutated Chronic Lymphocytic Leukemia (CLL): Indications for the Therapeutic Use of VEGF-Signaling Inhibitors.

Effective Targeting of MEK/ERK Signalling at Nanomolar Concentrations by the Novel Small Molecule Inhibitor PD0325901 in Hematopoietic and Solid Tumors.

Detection of the NUP214-ABL Rearrangement in T-ALL by High-Density Oligonucleotide Arrays: Evidence of the Value of This Approach in the Identification of Gene Amplifications.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only